Current market catalysts

Macquarie Maintains Outperform on Zscaler, Raises Price Target to $200

Macquarie analyst Steve Koenig maintains Zscaler (NASDAQ:ZS) with a Outperform and raises the price target from $172 to $200.

Congressman Sells Apple Two Weeks Before CEO Change, Buys Another Magnificent Seven Stock

A congressman may have a new favorite Magnificent Seven stock with a recent transaction showing the sale of one name and buy of another.

Macquarie Maintains Neutral on Snowflake, Raises Price Target to $350

Macquarie analyst Steve Koenig maintains Snowflake (NYSE:SNOW) with a Neutral and raises the price target from $200 to $350.

Want to Play Political Versions of Games like Tetris, Flappy Bird and Snake? The White House Hopes You Do

The White House released new retro arcade games that show off President Donald Trump's policies. Here's why the games look so familiar.

OpenAI’s AI Agents Went Rogue on German Website

OpenAI agents were tied to an incident that turned a German-language wiki into a coordination hub for other automated systems.

Lululemon’s Margin Problem Could Spell Trouble for These ETFs

Lululemon's margin pressure raises concerns for consumer ETFs as weak sales, tariffs, and competition test retail profitability.

Blue Owl’s Tech Fund Is Raising Debt While its Shares Sink 21% Year-To-Date

Blue Owl Technology Financial has returned to the market for its third financing since June, marking a steady run of fundraising activity.

Redemptions Ease at KKR's Private Credit Fund as Rivals Cap Withdrawals

KKR & Co’s (NYSE: KKR) private credit fund for wealthy clients outside the U.S. has seen redemption requests ease.

Premiumization and Strong Brands Fuel Constellation Brands' Growth

Constellation Brands (STZ) is focusing on premium brands like Modelo, Corona, and Pacifico to drive growth and improve margins. The company's strategy emphasizes brand building, premiumization, and cost efficiency. However, STZ shares have underperformed the industry, declining 7.7% in three months, and carry a Zacks Rank #3 (Hold) rating with modest earnings growth projections.

Realty Income's Industrial Expansion: Can it Lift Long-Term Returns?

Realty Income (O) is significantly expanding its industrial real estate portfolio, allocating about 75% of Q2 U.S. investments to warehouses and logistics. Industrial assets now represent 65% of global investments with stronger rent escalators (2-3.5% annually) and a 105.8% rent recapture rate. The company raised 2026 AFFO guidance to $4.44-$4.45 per share, with Q2 AFFO per share rising 3.8% to $1.09, though net debt remains elevated at 5.4x EBITDAre.

Here's Why Investors Should Retain Powell Industries Stock in Portfolio Now

Powell Industries (POWL) reported strong Q3 fiscal 2026 results with 9% revenue growth to $311.7M and record new orders of $934.2M (up 158% YoY), driven by growth in electric utility and commercial/industrial markets. The company is expanding its Jacintoport facility by 335,000 sq ft to support over $100M in annualized revenues. However, rising operating costs and material inflation present headwinds. POWL is rated Zacks Rank #3 (Hold) and has gained 69.8% year-to-date.

Can Higher ARPU Keep Spotify's Premium Revenue Growing?

Spotify reported 15% year-over-year growth in Premium revenues to €4.33B, driven by 9% subscriber growth and 7% ARPU increases from price hikes. Ad-Supported revenues grew only 1% despite improvements in podcast sponsorships, with music advertising facing pricing pressure. The company's focused strategy on subscriber and monetization gains positions it competitively against Apple and Amazon in the streaming market.

Should You Buy, Sell or Hold PVH Stock Post Q2 Earnings?

PVH Corp. delivered mixed Q2 fiscal 2026 results with revenues down 3% but profitability exceeding expectations, boosted by $107 million in tariff refunds. The company maintained momentum in direct-to-consumer and e-commerce channels while facing headwinds from wholesale weakness and soft international demand. PVH reaffirmed full-year EPS guidance of $11.80-$12.10 but projects a more challenging Q3 with low single-digit revenue declines.

SoFi Technologies Teams Up With Payward: Will SoFiUSD Gain Traction?

SoFi Technologies has partnered with Payward (Kraken's parent company) to integrate banking services with digital-asset markets. SoFiUSD stablecoin will be listed on Kraken, while Payward gains access to SoFi's Exchange Network for 24/7 dollar clearing. SoFi reported $300 million in SoFiUSD circulation in Q2 2026 and 388,336 crypto products, with net crypto revenues reaching $1.18 million.

Elon Musk Predicts SpaceX Will Generate $3.5 Trillion in Revenue by 2033. History Suggests He Will Be Wrong Yet Again.

Elon Musk predicted SpaceX could generate $3.5 trillion in revenue by 2033, but analyst Adam Spatacco argues this is unrealistic. SpaceX currently generates ~$12.5 billion in revenue (H1 2026) and would need 86% annual growth to reach the target. The article highlights Musk's history of missing timelines at Tesla with autonomous driving, robotaxis, and Cybertruck, suggesting similar overoptimism surrounds SpaceX's projection.

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Innventure, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INV

Rosen Law Firm has filed a class action lawsuit against Innventure, Inc. (NASDAQ: INV) on behalf of investors who purchased securities between November 17, 2025 and August 13, 2026. The lawsuit alleges that defendants made materially false and misleading statements regarding Accelsius Holdings LLC's transformative deal with DarkNX, which was unlikely to materialize, and that revenue and cash flow targets for 2026 were overstated. Investors who wish to serve as lead plaintiff must file by October 27, 2026.

High Roller Technologies to Present at the Sidoti Small-Cap Virtual Conference

High Roller Technologies (NYSE: ROLR), an online gaming and prediction markets company, announced that its management team will present at the Sidoti Small-Cap Virtual Conference on September 23-24, 2026. The company will deliver presentations and participate in one-on-one investor meetings during the virtual event.

Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?

The biotech industry is experiencing a strong rebound in 2026. While both Vertex Pharmaceuticals and Regeneron are attractive options, Vertex emerges as the better buy due to its stronger competitive advantage in cystic fibrosis drugs with patent protection until the late 2030s, diversified pipeline targeting high-need areas with less competition, and lower execution risk compared to Regeneron's dependence on weight-loss candidates and defending its Dupixent franchise against increasing competition.

The Nasdaq, S&P 500, and Dow All Fell Slightly Friday. The Jobs Report Wasn't Really Why.

Major U.S. stock indexes fell modestly on Friday despite a stronger-than-expected August jobs report showing 162,000 payroll additions versus consensus of 53,000. The strong jobs data raised Fed rate hike odds to 60% for the September meeting, causing short-term Treasury yields to spike. Apple weighed on the market due to production issues with foldable devices, while Tesla dropped 6% following disappointing early reviews of its Cybercab service. Micron Technology surged on plans to double AI memory chip production by 2027.

XTI AEROSPACE INVESTOR ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against XTI Aerospace, Inc. and Encourages Investors to Contact the Firm

A class action lawsuit has been filed against XTI Aerospace, Inc. in the U.S. District Court for the Southern District of New York. The lawsuit alleges that senior executives engaged in undisclosed activities and made materially false and misleading statements about the company's business operations and prospects during the period of April 15, 2026 to August 17, 2026. Investors who purchased XTI securities during this period and suffered losses are encouraged to contact the law firm.

Physical AI Infrastructure Market to Reach $327.21 Billion by 2035 as Robotics and Autonomous Systems Accelerate Global Demand | Research by SNS Insider

The global Physical AI Infrastructure Market is projected to grow from $14.20 billion in 2025 to $327.21 billion by 2035, with a CAGR of 36.91%. Growth is driven by deployment of AI systems in robotics, autonomous vehicles, smart factories, and edge computing. North America leads with 37% market share, while Asia-Pacific shows the fastest growth at 38.56% CAGR. Compute infrastructure and cloud deployment models dominate, with industrial automation and humanoid robotics as key applications.

Elauwit Investor News: If You Have Suffered Losses in Elauwit Connection, Inc. (NASDAQ: ELWT), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Rosen Law Firm is investigating potential securities claims against Elauwit Connection, Inc. (NASDAQ: ELWT) for allegedly issuing materially misleading business information. The company filed an 8-K on February 27, 2026, announcing a restatement of financial statements due to errors in network construction project revenue recognition during the first nine months of 2025. Following the announcement, Elauwit's stock price fell $0.52 per share (6.8%) to $7.12 on March 2, 2026. Investors who suffered losses are encouraged to join the class action lawsuit.

VAST Data and CrowdStrike Deliver First-of-Its-Kind Cybersecurity Across the AI Operating System

VAST Data and CrowdStrike announced new integrations bringing enterprise-grade cybersecurity across AI infrastructure, data access, and AI pipelines. The partnership integrates CrowdStrike Falcon sensor natively into VAST's AI Operating System, with planned integrations for Falcon Next-Gen SIEM and Falcon Guardian (AI Detection and Response). Native Falcon sensor support is available today, while SIEM and Guardian integrations are in private preview.

Ethos Chief Underwriter Nichole Myers Shares Why So Many Americans Are Still Waiting to Get Life Insurance on YourUpdateTV

Ethos research reveals that 72% of Americans wish they had purchased life insurance sooner, with 70% knowing they needed it before acting. The primary barrier is misconception about cost, though a healthy 30-year-old can obtain meaningful coverage for approximately $1 per day. Ethos has streamlined the application process to under 10 minutes online without medical exams, addressing historical delays of 6-8 weeks.

AI/R Everymind é premiada no Salesforce Partner of the Year Awards 2027

AI/R Everymind, a subsidiary of AI/R specializing in Agentic AI, won the Salesforce Partner of the Year Award 2027 in the inaugural Partner FDE Practice category. The award recognizes the company's expertise in deploying Agentforce from pilot to production at scale, leveraging its team of 500+ certified professionals and 2,000 successful Salesforce implementations.

Got $10,000 to Invest in This High-Yield, Midstream Stock? Here's What It Could Be Worth in 10 Years.

Hess Midstream LP (HESM) is highlighted as an attractive midstream energy investment opportunity, offering a 7.7% dividend yield with quarterly increases over nine years. The company operates oil, gas, and produced water handling assets in North Dakota's Bakken and Three Forks Shale plays. Its corporate structure was restructured in 2019 to simplify tax treatment for investors.

Why Apple Stock Sank on Friday

Apple stock dropped 2-3% on Friday following reports that its highly anticipated foldable iPhone is facing production challenges. Nikkei Asia reported that initial production is limited to only a few hundred units per day due to Apple's strict quality control standards, potentially making it difficult to meet market demand ahead of the holiday season. However, analysts note that Apple has a history of meeting deadlines and prioritizing quality over rushed timelines.

AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie has successfully diversified beyond its blockbuster Humira with strong immunology drugs (Skyrizi and Rinvoq), while Pfizer is leveraging its cash position to build oncology and GLP-1 pipelines. Despite AbbVie's stronger growth trajectory, Pfizer offers better valuation metrics with lower P/E and P/S ratios, making it the preferred choice for long-term value investors willing to wait for new product launches.

8-K filing — READING INTERNATIONAL INC (RDI)

Filed: 2026-09-04 AccNo: 0000716634-26-000032 Size: 204 KB Item 1.01: Entry into a Material Definitive Agreement

'Justice Department Hits Pause on Cooperation With Canadian Government' - WSJ Exclusive